Year: 2017
Type: review
Abstract: Down syndrome is caused by trisomy of chromosome 21. To date, a multiplicity of mouse models with Down-syndrome-related features has been developed to understand this complex human chromosomal disorder. These mouse models have been important for determining genotype-phenotype relationships and identification of dosage-sensitive genes involved in the pathophysiology of the condition, and in exploring the impact of the additional chromosome on the whole genome. Mouse models of Down syndrome have also been used to test therapeutic strategies. Here, we provide an overview of research in the last 15 years dedicated to the development and application of rodent models for Down syndrome. We also speculate on possible and probable future directions of research in this fast-moving field. As our understanding of the syndrome improves and genome engineering technologies evolve, it is necessary to coordinate efforts to make all Down syndrome models available to the community, to test therapeutics in models that replicate the whole trisomy and design new animal models to promote further discovery of potential therapeutic targets.
Source: Disease Models & Mechanisms
DOI: 10.1242/dmm.029728
Institutions: Centre National de la Recherche Scientifique, Inserm, Institut de génétique et de biologie moléculaire et cellulaire, Institut du Cerveau, Université de Strasbourg, Sorbonne Université, Sorbonne Paris Cité, Unit of Functional and Adaptive Biology, Université Paris Diderot, Université Pierre-et-Marie-Curie, UCL Queen Square Institute of Neurology, University College London, The Francis Crick Institute, Imperial College London, Roswell Park Comprehensive Cancer Center, University at Buffalo, State University of New York
Language: English
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,750
Funders: Roswell Park Alliance Foundation, Roswell Park Cancer Institute, Wellcome Trust, Francis Crick Institute, INFRAFRONTIER, Cancer Research UK, European Commission, Agence Nationale de la Recherche, Fondation Jérôme Lejeune, Institut National de la Santé et de la Recherche Médicale, Université de Strasbourg, Centre National de la Recherche Scientifique, PHENOMIN, National Institutes of Health, Medical Research Council, Sixth Framework Programme, Fifth Framework Programme, National Heart, Lung, and Blood Institute, National Cancer Institute, National Institute of General Medical Sciences, National Institute of Neurological Disorders and Stroke
Awards: G1086528976, Understanding Down Syndrome phenotypes through innovative mouse genetics., G1444014084, Ciblage thérapeutique de Dyrk1a dans des modèles de trisomie 21, G1883044511, G1923432458, G2170059015, Par-delà les frontières, l'Université de Strasbourg, G2325242462, Genetic Basis of Failed Cognition in Young and Aged Mouse Models of Trisomy 21, G2412404947, G2449524460, G2694206344, Understanding Down syndrome phenotypes through innovative mouse genetics., G3310169441, G3331289228, G3357951378, G415670728, G4571783231, G4899307531, G4911780241, G5175908573, Integrative Biology : Nuclear dynamics- Regenerative medicine - Translational medicine, G6518036048, G6581397394, G7002111755, G7233074485, G775812511, G7804020939, A genetic dissection of brain and heart phenotypes in the Tc1 transchromosomic mouse model of Down syndrome, INFRASTRUCTURE NATIONALE EN PHENOGENOMIQUE SOURIS, Genetic and Epigenetic Networks in Cognitive Dysfunction, Genetic Dissection of Trisomy 21, Mutational analysis to understand the role of CHML in developmental regression, Roswell Park Cancer Center Support Grant
OpenAlex ID: W2762704480
